FDA Approves Coagadex for Rare Blood Disorder


Factor X deficiency prevents blood from clotting properly.

Factor X deficiency prevents blood from clotting properly.

The FDA on Tuesday approved Coagadex, Coagulation Factor X (Human) to treat hereditary Factor X (10) deficiency. Until this approval, there was no particular coagulation factor replacement therapy available for patients with the condition.

The Factor X protein normally works by activating enzymes to help with normal blood clotting processes in the body. Factor X deficiency is a hereditary condition, affecting men and women at the same rate.

It is characterized by blood that does not clot properly. Patients with the condition are usually treated with fresh-frozen plasma or plasma-derived prothrombin complex concentrates to stop or prevent bleeding.

The availability of a purified Factor X concentrate increases treatment options for patients with this rare bleeding disorder.

“The approval of Coagadex is a significant advancement for patients who suffer from this rare but serious disease,” said Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research.

The new drug is made from human plasma and is intended for individuals aged 12 and older with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, and for perioperative management of bleeding in patients with a mild form of the condition.

Research was performed to evaluate the safety and efficacy of Coagadex in a multi-center, non-randomized study involving 16 participants (or 208 bleeding episodes) for treatment of spontaneous, traumatic, and heavy menstrual bleeding episodes.

The drug showed efficacy in controlling the bleeding episodes of patients who had severe hereditary Factor X deficiency. Coagadex was also analyzed in 5 patients who had a mild or severe form of the disease who were about to be operated on.

These individuals received the medication for perioperative management of seven surgical procedures. The medication was effective in the management of blood loss both during and after surgery in patients with a mild form of the deficiency.

No individuals with moderate or severe Factor X deficiency received Coagadex for perioperative management of major surgery, and no safety concerns were identified in either study.

The FDA granted orphan product designation to Coagadex for the aforementioned uses. In addition to orphan product designation, Coagadex was granted fast track designation and priority review.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.